{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:01:48Z","timestamp":1773828108663,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00280-021-04241-1","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T14:03:05Z","timestamp":1615298585000},"page":"717-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Detecting DPD deficiency: when perfect is the enemy of good"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-3410","authenticated-orcid":false,"given":"Joseph","family":"Ciccolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"4241_CR1","doi-asserted-by":"crossref","unstructured":"Burns KE, Chavani O, Jeong SH et al (2020) Comparison of a thymine challenge test and endogenous uracil\u2013dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer Chemother Pharmacol (EPub Ahead of Print)","DOI":"10.1007\/s00280-021-04240-2"},{"key":"4241_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Dahan L et al (2006) Toxic death-case after capecitabine\u2009+\u2009oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 58:272\u2013275","journal-title":"Cancer Chemother Pharmacol"},{"key":"4241_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V et al (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105","journal-title":"J Clin Oncol"},{"key":"4241_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3816\/CCC.2010.n.033","volume":"9","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (2010) Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9:224\u2013228","journal-title":"Clin Colorectal Cancer"},{"key":"4241_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639\u20131650","journal-title":"Lancet Oncol"},{"key":"4241_CR6","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2018). Des recommandations pour pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res des chimioth\u00e9rapies par fluoropyrimidines. https:\/\/www.has\u2010sante.fr\/portail\/jcms\/c_2892234\/fr\/des\u2010recommandations\u2010pour\u2010prevenir\u2010certaines\u2010toxicites\u2010severes\u2010des\u2010chimiotherapies\u2010par\u2010fluoropyrimidines. Accessed 1 Oct 2020"},{"key":"4241_CR7","unstructured":"EMA recommendations on DPD testing (2020). https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Accessed 1 Oct 2020"},{"key":"4241_CR8","unstructured":"Medicines & Healthcare products Regulatory Agency (2020). https:\/\/www.DrugSafetyUpdate-GOV.UK. Accessed 5 Oct 2020"},{"key":"4241_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34:227\u2013234","journal-title":"J Clin Oncol"},{"key":"4241_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, van der Wouden CH, Nijenhuis M et al (2020) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28:508\u2013517","journal-title":"Eur J Hum Genet"},{"key":"4241_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2217\/pgs-2016-0013","volume":"17","author":"CA Lunenburg","year":"2016","unstructured":"Lunenburg CA, van Staveren MC, Gelderblom H, Guchelaar HJ, Swen JJ (2016) Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics 17:721\u2013729","journal-title":"Pharmacogenomics"},{"key":"4241_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459\u20131467","journal-title":"Lancet Oncol"},{"key":"4241_CR13","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248\u20132253","journal-title":"J Clin Oncol"},{"key":"4241_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","volume":"672","author":"S Sumi","year":"1995","unstructured":"Sumi S, Kidouchi K, Ohba S, Wad Y (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B, Biomed Appl 672:233\u2013239","journal-title":"J Chromatogr B, Biomed Appl"},{"key":"4241_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/FTD.0000000000000615","volume":"41","author":"MV Antunes","year":"2019","unstructured":"Antunes MV, Raymundo S, Cezimbra da Silva AC et al (2019) Determination of endogenous concentrations of uracil and dihydrouracil in dried saliva spots by LC\u2013MS\/MS: method development, validation, and clinical application. Ther Drug Monit 41:383\u2013390","journal-title":"Ther Drug Monit"},{"key":"4241_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/cts.12762","volume":"13","author":"C Marin","year":"2020","unstructured":"Marin C, Krache A, Palmaro C et al (2020) A simple and rapid UPLC-UV method for detecting DPD deficiency in patients with cancer. Clin Transl Sci 13:761\u2013768","journal-title":"Clin Transl Sci"},{"key":"4241_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","volume":"67","author":"CG Yang","year":"2011","unstructured":"Yang CG, Ciccolini J, Blesius A et al (2011) DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 67:49\u201356","journal-title":"Cancer Chemother Pharmacol"},{"key":"4241_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","volume":"4","author":"M Launay","year":"2017","unstructured":"Launay M, Ciccolini J, Fournel C et al (2017) Upfront DPD deficiency detection to secure 5-Fu administration: part 2\u2014application to head-and-neck cancer patients. Clin Cancer Drugs 4:122\u2013128","journal-title":"Clin Cancer Drugs"},{"key":"4241_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/bcp.12821","volume":"81","author":"MC van Staveren","year":"2016","unstructured":"van Staveren MC, van Kuilenburg AB, Guchelaar HJ et al (2016) Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. Br J Clin Pharmacol 81:553\u2013561","journal-title":"Br J Clin Pharmacol"},{"key":"4241_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1515\/cclm-2018-1177","volume":"57","author":"S Mindt","year":"2019","unstructured":"Mindt S, Aida S, Merx K et al (2019) Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. Clin Chem Lab Med 57:1012\u20131016","journal-title":"Clin Chem Lab Med"},{"key":"4241_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"MA Loriot","year":"2018","unstructured":"Loriot MA, Ciccolini J, Thomas F et al (2018) Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105:397\u2013407","journal-title":"Bull Cancer"},{"key":"4241_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 103:210\u2013216","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-021-04241-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T16:15:36Z","timestamp":1617812136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-021-04241-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4241"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04241-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"6 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"I, Pr Joseph Ciccolini, on behalf of all co-authors of the paper referenced as above, declare that none of the authors have direct or indirect conflict of interest to disclose in relationship with the published work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}